Your browser is no longer supported. Please, upgrade your browser.
CVAC [NASD]
CureVac N.V.
Index- P/E- EPS (ttm)- Insider Own55.92% Shs Outstand188.18M Perf Week-3.62%
Market Cap7.91B Forward P/E- EPS next Y-2.09 Insider Trans0.00% Shs Float84.22M Perf Month10.57%
Income- PEG- EPS next Q-0.64 Inst Own23.30% Short Float4.84% Perf Quarter-38.78%
Sales76.50M P/S103.41 EPS this Y-26.40% Inst Trans-0.65% Short Ratio5.81 Perf Half Y-60.26%
Book/sh- P/B- EPS next Y374.00% ROA- Target Price62.80 Perf Year-67.67%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range35.05 - 151.80 Perf YTD-48.14%
Dividend- P/FCF- EPS past 5Y- ROI-14.20% 52W High-72.31% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low19.94% ATR3.06
Employees500 Current Ratio- Sales Q/Q463.50% Oper. Margin- RSI (14)49.68 Volatility7.20% 6.84%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.44 Prev Close45.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume701.06K Price42.04
Recom2.70 SMA203.36% SMA500.17% SMA200-41.61% Volume996,647 Change-6.58%
Oct-22-21Initiated Deutsche Bank Hold $35
Jun-17-21Downgrade BofA Securities Buy → Neutral $50
Apr-26-21Resumed Credit Suisse Underperform
Apr-26-21Initiated Guggenheim Neutral
Dec-10-20Downgrade Credit Suisse Neutral → Underperform $50 → $47
Sep-08-20Initiated Jefferies Hold $58
Sep-08-20Initiated Credit Suisse Neutral $68
Sep-08-20Initiated BofA Securities Buy $70
Dec-08-21 09:21AM  
Dec-03-21 02:35PM  
Nov-29-21 11:07AM  
Nov-19-21 01:30PM  
02:00AM  
Nov-18-21 09:43AM  
08:20AM  
06:10AM  
Nov-10-21 08:26AM  
07:15AM  
Oct-28-21 07:26AM  
Oct-14-21 10:41AM  
Oct-12-21 11:12AM  
11:10AM  
09:42AM  
08:43AM  
08:34AM  
08:24AM  
07:20AM  
07:15AM  
06:13AM  
04:50AM  
04:37AM  
04:09AM  
Sep-27-21 10:31AM  
Sep-23-21 12:12PM  
Sep-14-21 09:54AM  
07:49AM  
07:30AM  
Sep-07-21 04:05PM  
Sep-01-21 12:47PM  
Aug-31-21 07:15AM  
Aug-30-21 07:15AM  
Aug-27-21 07:04AM  
Aug-19-21 09:30AM  
Aug-18-21 11:47AM  
Aug-17-21 09:58AM  
07:50AM  
Aug-16-21 10:40AM  
10:30AM  
08:32AM  
07:15AM  
05:01AM  
04:34AM  
Jul-21-21 08:00PM  
Jul-20-21 11:01AM  
Jul-10-21 06:00AM  
Jul-07-21 12:56PM  
Jul-04-21 07:31AM  
06:00AM  
Jul-03-21 07:00AM  
06:15AM  
Jul-01-21 10:58AM  
09:03AM  
04:34AM  
03:52AM  
02:34AM  
02:15AM  
02:00AM  
Jun-30-21 04:59PM  
04:45PM  
04:30PM  
11:13AM  
07:12AM  
Jun-29-21 07:19AM  
Jun-25-21 12:35AM  
Jun-23-21 11:08AM  
07:45AM  
06:00AM  
05:55AM  
Jun-22-21 05:52AM  
Jun-21-21 07:29AM  
06:13AM  
04:09AM  
Jun-18-21 10:54AM  
10:40AM  
06:30AM  
06:18AM  
Jun-17-21 04:46PM  
04:29PM  
04:13PM  
04:01PM  
03:55PM  
12:36PM  
12:14PM  
11:20AM  
11:06AM  
10:41AM  
10:32AM  
10:30AM  
10:26AM  
10:19AM  
08:35AM  
08:17AM  
07:08AM  
06:44AM  
06:25AM  
05:07AM  
05:04AM  
04:09AM  
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tubingen, Germany.